Cbay stock forecast.

Cymabay Therapeutics 's revenue in 2023 is $31,016,000. On average, 7 Wall Street analysts forecast CBAY's revenue for 2023 to be $3,523,442,178, with the lowest CBAY …provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their research and their ... Weather forecasting plays a crucial role in our daily lives, helping us plan our activities and make informed decisions. But have you ever wondered how meteorologists are able to accurately predict the weather? One of the key components in ...Find the latest CymaBay Therapeutics, Inc. (CBAY) stock quote, history, news and other vital information to help you with your stock trading and investing. CymaBay Therapeutics ( NASDAQ: CBAY) is a clinical-stage biopharmaceutical company aiming to develop innovative treatments for liver diseases and other chronic conditions with high unmet medical ...

Find real-time ALDX - Aldeyra Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Dec 1, 2023 · CBAY Earnings Date and Information. CymaBay Therapeutics last posted its earnings results on November 7th, 2023. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.02. Stem, Inc. (NYSE:STEM) released its earnings results on Thursday, November, 2nd. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01. The firm had revenue of $133.74 million for the quarter, compared to the consensus estimate of $182.46 million.Cymabay Therapeutics Inc (NASDAQ:CBAY) trade information. Instantly CBAY has been showing red trend so far today with a performance of -1.24% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently up 186.68% year-to-date, but still down -3.67% over the …

The average twelve-month price prediction for CymaBay Therapeutics is $22.27 with a high price target of $34.00 and a low price target of $12.00. Learn more on CBAY's analyst rating history. Do Wall Street analysts like CymaBay Therapeutics more than its competitors?

Find the latest Allarity Therapeutics, Inc. (ALLR) stock quote, history, news and other vital information to help you with your stock trading and investing.

September 8, 2023 at 1:12 PM · 3 min read. Shares of clinical-stage biopharmaceutical company CymaBay Therapeutics, Inc. CBAY gained after it announced positive top-line results from its late ...CBAY is a biotechnology company that develops treatments for neurological disorders. The stock price forecast shows a strong buy signal from the 3-month …For CymaBay Therapeutics stock forecast for 2023, 1 predictions are offered for each month of 2023 with average CymaBay Therapeutics stock forecast of $19.97, a high forecast of $19.97, and a low forecast of $19.97. The average CymaBay Therapeutics stock forecast 2023 represents a 4.58% increase from the last price of $19.1000003814697.CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary ...Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY), Mersana Therapeutics (MRSN) and Verona Pharma (VRNA) November 8, 2023 TipRanks.Reported on 11/6/23. Get the latest CymaBay Therapeutics Inc (CBAY) real-time quote, historical performance, charts, and other financial information to help you make more …Stem, Inc. (NYSE:STEM) released its earnings results on Thursday, November, 2nd. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01. The firm had revenue of $133.74 million for the quarter, compared to the consensus estimate of $182.46 million.

Their ZOM share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 3,421.1% from the stock's current price. View analysts price targets for ZOM or view top-rated stocks among Wall Street analysts.Find real-time TNEYF - Tamarack Valley Energy Ltd stock quotes, company profile, news and forecasts from CNN Business.We’ve all flipped between different weather apps, wondering why each is giving a slightly different report. Before we look at AccuWeather, it’s important to understand the basics of weather forecasting. In the past, weather predictions were...Average target price for CBAY - CymaBay Therapeutics is predicted at $2.2462 within next 1 yearWhat happened. Shares of CymaBay Therapeutics ( CBAY 4.87%) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced ...NextPlay Technologies, Inc. (NASDAQ:NXTP) announced its quarterly earnings results on Wednesday, January, 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. The firm earned $4.20 million during the quarter, compared to the consensus estimate of $5.70 …

A price increase of 41.9% over the past four weeks ensures that the trend is still in place for the stock of this company. Moreover, CBAY is currently trading at 92.9% of its 52-week High-Low ...CymaBay Therapeutics Inc. 18.65. Delayed Data. As of Nov 20. +0.30 / +1.63%. Today’s Change. 3.17. Today ||| 52-Week Range. 18.81.

Analyst Forecast. According to 12 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price forecast is $22.64, which is an increase of 18.35% from the latest price.CBAY is a biopharmaceutical company that develops and commercializes new medicines for important human diseases. The stock price, earnings, news, and research reports of CBAY are available on Zacks. See the latest Zacks Rank, Style Scores, EPS Surprise, and more for CBAY.Predicting the weather has long been one of life’s great mysteries — at least for regular folks. Over the years, you’ve probably encountered a few older adults — maybe even your own grandparents — who made some weather predictions based on ...Predictions of CBAY stock price for tomorrow. 14-day Premium Trial Subscription Try For Free Get FreeXenon Pharmaceuticals Inc. 28.97. +0.24. +0.84%. Get CymaBay Therapeutics Inc (CBAY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Find real-time ALDX - Aldeyra Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.Find the latest Allarity Therapeutics, Inc. (ALLR) stock quote, history, news and other vital information to help you with your stock trading and investing.The average Guardforce Ai Co stock price prediction forecasts a potential upside of 260.82% from the current GFAI share price of $3.88. What is GFAI's forecast return on assets (ROA) for 2023-2026? (NASDAQ: GFAI) forecast ROA is N/A, which is lower than the forecast US Security & Protection Services industry average of N/A.

Find real-time CPG - Crescent Point Energy Corp stock quotes, company profile, news and forecasts from CNN Business.

The above table shows the analyst CBAY forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$18.03

Cymabay Therapeutics Stock Chart and Share Price Forecast, Short-Term "CBAY" Stock Prediction for Next Days and Weeks Walletinvestor.com Cymabay Therapeutics Inc (CBAY) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024Stock Price Forecast The 6 analysts offering 12-month price forecasts for Aldeyra Therapeutics Inc have a median target of 9.00, with a high estimate of 11.00 and a low estimate of 7.00.Based on short-term price targets offered by 11 analysts, the average price target for CymaBay Therapeutics Inc. comes to $22.73. The forecasts range from a low …View Coterra Energy Inc CTRA investment & stock information. Get the latest Coterra Energy Inc CTRA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Nov 3, 2023 · Cymabay Therapeutics Inc (NASDAQ:CBAY) trade information. Cymabay Therapeutics Inc (CBAY) has traded red over the past five days. The stock hit a weekly high of 16.87 this Thursday, 11/02/23. The 5-day price performance for the stock is 8.04%, and 17.06% over 30 days. With these gigs, the year-to-date price performance is 161.56%. Track Cymabay Therapeutics Inc (CBAY) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Is Cymabay Therapeutics (NASDAQ:CBAY) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, ...Nov 27, 2023 · See the latest CymaBay Therapeutics Inc stock price (CBAY:XNAS), related news, valuation, dividends and more to help you make your investing decisions. CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) NEWARK, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced …Ra Medical Systems, Inc (NYSE:RMED) released its quarterly earnings results on Monday, November, 15th. The company reported ($57.50) earnings per share for the quarter, missing the consensus estimate of ($39.50) by $18.00. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.70 million.CBAY stock performances on November 6, 2023, are expected to be positive based on the information provided. According to data from CNN Money, the 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc have a median target of $22.50, with a high estimate of $33.00 and a low estimate of $19.00.View the latest CymaBay Therapeutics Inc. (CBAY) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Xenon Pharmaceuticals Inc. 28.97. +0.24. +0.84%. Get CymaBay Therapeutics Inc (CBAY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Cymabay Therapeutics Inc (NASDAQ:CBAY) trade information. Instantly CBAY has been showing red trend so far today with a performance of -1.24% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently up 186.68% year-to-date, but still down -3.67% over the …18 brokers have issued twelve-month target prices for Coterra Energy's stock. Their CTRA share price targets range from $27.00 to $42.00. On average, they anticipate the company's stock price to reach $31.93 in the next year. This suggests a possible upside of 19.3% from the stock's current price.CymaBay Therapeutics Stock Forecast 2023. In the last five quarters, CymaBay Therapeutics’s Price Target has fallen from $29.28 to $23.09 - a -21.14% decrease. Five analysts predict that CymaBay Therapeutics’s share price will fall in the coming year, reaching $10.00. This would represent a decrease of -56.69%.Instagram:https://instagram. syld etftop losers stocks todaysanmina sci stockmercury dime prices Cymabay Therapeutics Stock Chart and Share Price Forecast, Short-Term "CBAY" Stock Prediction for Next Days and Weeks Walletinvestor.com Cymabay Therapeutics Inc (CBAY) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024CBAY Overview Stock Screener Earnings Calendar Sectors Nasdaq CBAY U.S.: Nasdaq CymaBay Therapeutics Inc. Watch list Alert After Hours Last Updated: Nov 17, 2023 6:04 … paypal to western unionringcentral ceo CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary ... vanguard high yield etf Find real-time MCOM - micromobility.com inc stock quotes, company profile, news and forecasts from CNN Business.Research CymaBay Therapeutics' (Nasdaq:CBAY) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more. ... Revenue is forecast to grow 61.55% per year. Risk Analysis. Currently unprofitable and not forecast to become profitable over the next 3 years.